Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Dr. Mesri coordinates activities of several cancer working groups in the Office of Cancer Clinical Proteomics Research (OCCPR), including the Clinical Proteomic Tumor Analysis Consortium (CPTAC). In this role, he provides oversight and contributes to disease groups aims and directions. Dr. Mesri also provides leadership in integrating emerging technologies for the development of cancer protein diagnostics and therapeutics including management and dissemination of targeted proteomic assays.  He coordinates activities with NCI's Small Business Innovation Research (SBIR) Office and manages OCCPR proteomics investigator grants.

Dr. Mesri joined DCTD’s OCCPR in 2007 as a Program Director. Prior to the NCI, Dr. Mesri served as a principal scientist/projects leader in the Department of Protein Therapeutics at Celera.  There, he used mass spectrometry technologies to discover and validate biologic antibody targets in oncology, including prostate and lung cancers and angiogenesis.  Prior to that, Dr. Mesri was a project leader at CuraGen Corporation, where he investigated genomically-derived high value protein drugs and fully human monoclonal antibody targets for cancer and immunology/inflammation programs, among other responsibilities.  Dr. Mesri was a post-doctoral fellow and then a Research Scientist at Yale University School of Medicine in the laboratory of Dr. Dario Altieri where he spent 5 years studying adhesion molecules and later, therapeutic targeting of the Survivin pathway in cancer gene therapy.

Education

  • Ph.D., Immunology, The University of Aberdeen, Aberdeen, UK.
  • M. Med. Sci., Clinical Pathology, The University of Sheffield, Sheffield, UK.
  • BSc., Biomedical Sciences, The University of Bradford, Bradford, UK.
Email